- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Betta Pharmaceuticals Co Ltd (300558)
Betta Pharmaceuticals Co Ltd stock price live, this page displays SZ 300558 stock exchange data. View the 300558 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Betta Pharmaceuticals Co Ltd real time stock price chart below.
What Is the Betta Pharmaceuticals Co Ltd Stock Price Today?
The Betta Pharmaceuticals Co Ltd stock price today is 52.94.
What Is the Stock Symbol for Betta Pharmaceuticals Co Ltd?
The stock symbol for Betta Pharmaceuticals Co Ltd is "300558."
What Stock Exchange Does Betta Pharmaceuticals Co Ltd Trade On?
Betta Pharmaceuticals Co Ltd is listed and trades on the Shenzhen stock exchange.
Is Betta Pharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether Betta Pharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300558 quote. (ISIN: CNE100002DD9)
What Is the Betta Pharmaceuticals Co Ltd Stock Price Today?
The Betta Pharmaceuticals Co Ltd stock price today is 52.94.
What Is the Stock Symbol for Betta Pharmaceuticals Co Ltd?
The stock symbol for Betta Pharmaceuticals Co Ltd is "300558."
What Stock Exchange Does Betta Pharmaceuticals Co Ltd Trade On?
Betta Pharmaceuticals Co Ltd is listed and trades on the Shenzhen stock exchange.
Is Betta Pharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether Betta Pharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300558 quote. (ISIN: CNE100002DD9)
Shenzhen
Currency in CNY
52.94
-0.01(-0.02%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.73
53.82
52 wk Range
40.10
79.80
300558 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.7353.82
52 wk Range
40.1079.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
300558 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
43.06
Downside
-18.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 43.06
(-18.66% Downside)
Earnings
Latest Release
Apr 23, 2026
EPS / Forecast
0.56 / --
Revenue / Forecast
1.04B / --
Compare 300558 to Peers and Sector
Metrics to compare | 300558 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300558PeersSector | |
|---|---|---|---|---|
P/E Ratio | 50.5x | 40.0x | −0.5x | |
PEG Ratio | 5.99 | 0.68 | 0.00 | |
Price/Book | 3.3x | 2.4x | 2.6x | |
Price / LTM Sales | 6.0x | 3.3x | 3.2x | |
Upside (Analyst Target) | −18.7% | 35.4% | 48.3% | |
Fair Value Upside | Unlock | 10.9% | 5.6% | Unlock |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met. In addition, the company develops BPI-371153 for the treatment of patients with locally advanced or metastatic solid tumor or relapsed/refractory lymphoma; CFT8919, an in vitro and in vivo model of EGFR L858R-driven NSCLC; and Balstilimab, a human monoclonal antibody targeting programmed cell death protein 1 and an immune checkpoint inhibitor. Further, it develops a recombinant human serum albumin injection under the OsrHSA name; and products for the treatment of solid tumor under the BPI-452080, MRX2843, BPI-460372, BPI-221351, BPI-520105, BPI-572270, and BPI-585725 names. The company was founded in 2003 and is headquartered in Hangzhou, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Betta Pharma (300558) Stock Price Today?
The Betta Pharma stock price today is 52.94 CNY.
What Stock Exchange Does Betta Pharma Trade On?
Betta Pharma is listed and trades on the Shenzhen Stock Exchange.
What Is the Stock Symbol for Betta Pharma?
The stock symbol for Betta Pharma is "300558."
Does Betta Pharma Pay Dividends? What’s The Current Dividend Yield?
The Betta Pharma dividend yield is 0.38%.
What Is the Betta Pharma Market Cap?
As of today, Betta Pharma market cap is 22.28B CNY.
What Is Betta Pharma's Earnings Per Share (TTM)?
The Betta Pharma EPS (TTM) is 1.05.
When Is the Next Betta Pharma Earnings Date?
Betta Pharma will release its next earnings report on Apr 24, 2026.
From a Technical Analysis Perspective, Is 300558 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Betta Pharma Stock Split?
Betta Pharma has split 0 times.
How Many Employees Does Betta Pharma Have?
Betta Pharma has 1785 employees.
What is the current trading status of Betta Pharma (300558)?
As of May 07, 2026, Betta Pharma (300558) is trading at a price of 52.94 CNY, with a previous close of 52.95 CNY. The stock has fluctuated within a day range of 52.73 CNY to 53.82 CNY, while its 52-week range spans from 40.10 CNY to 79.80 CNY.
What Is Betta Pharma (300558) Price Target According to Analysts?
The average 12-month price target for Betta Pharma is 43.06 CNY, with a high estimate of 43.06 CNY and a low estimate of 43.06 CNY. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -18.66% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.